We are delighted to announce that 5 new projects have been selected by the Paris-Saclay Cancer Paris (PSCC) to benefit from its support: BlueBees, Klineo, Inen Robotics, Biogenera and a start-up in creation.
This month's shortlist highlights groundbreaking innovations in biotechnology, digital health, and medical devices, with a focus on improving oncology treatment and care.
BlueBees develops first-in-class immunotherapies for the treatment of cancer based on disruptive technology that potentiates the ability of antibodies to activate immune cells.
Klineo offers a digital health platform enabling intuitive, intelligent and rapid research of clinical trials, thereby facilitating patient access to new therapeutic options.
Inen Robotics creates robotic solutions for gastroenterology operations, enabling precise interventions to be performed while reducing the risk of complications.
Biogenera specializes in the research and development of personalized DNA-based biotechnology medicines. Their exclusive MyGeneraTM platform identifies and develops molecules specifically targeting mutated genes responsible for diseases, with a first product in pediatric oncology targeting the MYCN gene.
In addition to these projects, we are also delighted to support a start-up in creation, the details of which will be revealed soon. These developments represent a promising leap forward in the field of oncology and are expected to improve patient care and outcomes.
With 44 cutting-edge oncology projects selected and supported, PSCC offers the most promising developers access to a comprehensive set of resources to accelerate oncology innovation: expertise, networking, funding, data, samples, technologies , infrastructure, training, laboratories.
Are you developing an innovative solution for oncology patients? Join us: https://www.parissaclaycancercluster.org/en/postulez
Komentáře